Medtronic

• Hugo RAS System
• Mazor X Stealth Edition

• Customer site

  2026-02-17 - Medtronic Hugo RAS performed its first U.S. commercial surgery at Cleveland Clinic. - first U.S. commercial surgical case - Cleveland Clinic

  Source

Supply chain relationships

• Cornerstone Robotics

  Inbound - Equipment - Cornerstone Robotics supplies Sentire surgical-system distribution rights for approved markets outside the United States

  Source
• NVIDIA

  Inbound - Robotics Compute - NVIDIA identifies Medtronic as an early Jetson Thor adopter

  Source
• Titan Medical

  Inbound - Software - Titan Medical supplies robotic-surgery technology licence for Medtronic surgical-robotics development programme

  Source

• MDT - NYSE - USD

• Geoff Martha - Chairman and Chief Executive Officer - Medtronic's surgical, spine and robotic-enabled therapy portfolio sits within the global medtech strategy.
• Scott Cundy - SVP and Chief Quality, Development, and Innovation Officer

Events

• 2026-09-16 - Regulatory - Medtronic adds FDA-cleared LigaSure vessel sealer to Hugo

  The instrument seals and cuts vessels, thick tissue and lymphatics up to 7 mm in diameter and is designed for the Valleylab FT10 energy platform. Hugo is currently cleared for urologic procedures in the United States; Medtronic is pursuing broader soft-tissue indications. The LigaSure RAS Maryland instrument had been introduced on Hugo in Europe in 2025 after CE marking.

  Source
• 2026-09-01 - Partnership - Cornerstone Robotics and Medtronic sign Sentire distribution partnership

  The approximately $700 million investment includes distribution rights for Sentire in select markets outside the United States where the system is approved. Medtronic plans to offer Sentire alongside its Hugo RAS surgical system. Sentire received CE Mark in May 2026 and has market approvals in China and Singapore.

  Source
• 2026-05-20 - Partnership - Medtronic and Asan Medical Center partner on Hugo robotic surgery

  The collaboration covers clinical research, education and technology development around Hugo RAS. The agreement followed Hugo regulatory approvals in Europe, Japan, Korea and the U.S.

  Source
• 2026-02-17 - Deployment - Medtronic Hugo RAS performs first U.S. commercial surgery at Cleveland Clinic

  The procedure was performed at Cleveland Clinic by Jihad Kaouk, MD. The patient underwent robotic-assisted prostatectomy and was discharged the next day. The deployment places The company's technology into commercial automation and autonomous-system workflows beyond a lab-only setting.

  Source
• 2025-12-03 - Regulatory - Medtronic receives FDA clearance for Hugo robotic-assisted surgery system

  Medtronic received U.S. FDA clearance for the Hugo robotic-assisted surgery system for urologic procedures. The clearance was supported by the Expand URO clinical study in multi-port robotic-assisted urological surgery. The decision brings Hugo into the U.S. soft-tissue robotic surgery market alongside Medtronic's broader surgical portfolio.

  Source
• 2025-10-08 - Regulatory - Medtronic starts U.S. Hugo RAS gynecology IDE study

  The Embrace Gynecology study became Medtronic’s third U.S. IDE clinical study for Hugo RAS. Medtronic said the study supported its strategy to pursue multiple U.S. indications for Hugo RAS. The approval supports Medtronic starts U.S. Hugo RAS gynecology IDE study's path toward fielded use in commercial automation and autonomous-system workflows.

  Source
• 2025-04-26 - Market Signal - Medtronic Expand URO trial meets Hugo RAS safety and effectiveness endpoints

  Medtronic announced that its Expand URO U.S. clinical trial for the Hugo RAS system met primary safety and effectiveness endpoints. The study evaluated Hugo RAS for urologic surgical procedures in the United States. Medtronic said the results supported its submission pathway for Hugo RAS in urology.

  Source
• 2023-06-05 - Acquisition - Medtronic buys selected Titan Medical patent rights

  Titan announced the asset purchase and licence agreement on June 5, 2023, with an upfront payment of US$8 million. Medtronic acquired patents it had previously licensed under the companies' 2020 agreements and received a non-exclusive licence to other Titan IP. Titan retained ownership of the additionally licensed IP and received a limited licence back to the acquired rights.

  Source
• 2022-10-19 - Regulatory - Medtronic expands Hugo approvals in Japan, Europe and Canada

  The approvals included Japan MHLW approval for urological and gynecological indications. The same announcement included CE Mark and Health Canada expansions for general surgery or laparoscopic indications.

  Source
• 2020-06-04 - Partnership - Titan Medical signs development and licence agreements with Medtronic

  Titan announced the agreements on June 4, 2020, with the contractual effective date recorded as June 3. The development programme covered robotic-assisted surgical technologies intended for use by both companies. Medtronic committed milestone payments of up to US$31 million for licensed technologies, while a separate IP licence carried an upfront US$10 million payment.

  Source
• 2019-01-28 - Product Launch - Medtronic launches Mazor X Stealth Edition in the US

  The system combined surgical planning, robotic guidance and real-time Stealth navigation. Initial U.S. procedures took place at Norton Healthcare and Reston Hospital Center. Medtronic reported that FDA clearance had been received in November 2018.

  Source

Relationships

• Titan Medical

  Licence Partner - Titan Medical licensed robotic-surgery technology to Medtronic and completed joint development work.

• Cornerstone Robotics

  Sentire Distribution Rights - Medtronic holds rights to distribute Cornerstone Robotics Sentire surgical system in select approved markets outside the United States.

• Mazor Robotics

  Acquired Spine Robotics Company - Medtronic acquired Mazor Robotics and continued its spine-surgery technology through Mazor X and later spine platforms.